沃森生物子公司收到13价肺炎结合疫苗埃及上市许可证

Core Viewpoint - Watson Bio (300142.SZ) announced that its subsidiary, Yuxi Watson Biotechnology Co., Ltd., has received a Biological Product Marketing License from the Egyptian Drug Authority (EDA) for its 13-valent pneumococcal polysaccharide conjugate vaccine, marking the vaccine's approval for sale in Egypt [1] Group 1 - The 13-valent pneumococcal conjugate vaccine is now licensed for sale in Egypt [1] - The approval from the Egyptian Drug Authority signifies a significant milestone for the company in expanding its market presence [1]